Moreover, by applying our LC-PRM-MS strategy, we were able to identify single and groups of haptoglobin N-glycopeptides that have potential to differentiate between patients with NASH cirrhosis and NASH-related HCC. This evidence concerns the gene HP and Cirrhosis.